An experimental lung cancer drug from Akeso and Summit Therapeutics reduced the risk of death by 34% in a late-stage trial, ...

A lung cancer drug reduced the risk of death by 34% in a late-stage trial, in the latest sign of China’s pharmaceutical ...

A 74-year-old Uttarakhand man, deemed too high-risk for lung cancer surgery due to severe breathing issues and diabetes, has ...

Experts have described the findings as a ‘promising step forward‘ for patients with advanced squamous non-small cell lung ...

Ivonescimab reduced the risk of death by one-third compared to chemotherapy in a China-based study that’s seen as an ...

While tobacco use remains one of the leading causes, there is growing evidence that environmental and genetic factors are ...

It’s the moment of truth for Akeso’s ivonescimab, and to many, a high-stakes test for China’s booming biotech industry. | ...

An experimental drug developed by China-based Akeso helped patients with advanced squamous non-small cell lung cancer live 15% longer than BeOne Medicines' immunotherapy Tevimbra, and cut the risk ...

When Garen was diagnosed with lung cancer, biomarker testing helped focus his treatment options, inform his treatment decisions, and finding the appropriate treatment has allowed him to maintain his ...

Despite recent advances in immunotherapy and targeted therapy, most patients with non-small-cell lung cancer (NSCLC) continue to have disease progression and develop resistance to current treatments.

Lung adenocarcinoma is the most common type of lung cancer diagnosed in the U.S. Just over half of all non-small-cell lung cancers (NSCLCs) are adenocarcinomas. Finding out that you're at risk of lung ...

A woman in England has died after being diagnosed with lung cancer, despite being a non-smoker. Juliet Fielder, known as ...